<div id="readability-page-1"><div><p>AtriCure (ATRC) recently issued a preliminary earnings update that pointed to a shift toward full year profitability in 2026, supported by guidance for revenue growth in the double digits and stronger adjusted EBITDA.</p> <p>See our latest analysis for AtriCure.</p> <p>The recent guidance and credit agreement amendment came after a sharp move higher around the earnings pre announcement. Yet the 1 year total shareholder return of 1.53% and 5 year total shareholder return of a 33.00% decline suggest only modest long term reward so far, while the 90 day share price return of 5.57% hints at momentum building more recently.</p> <p>If AtriCure's update has you looking across the sector, this could be a good moment to scan other medical names through healthcare stocks and see what stands out.</p> <p>With shares up in recent months but longer term returns still underwhelming, AtriCure now sits at an interesting crossroads. Is the market underestimating this profitability shift, or already baking in years of future growth?</p> <h2>Most Popular Narrative: 21.9% Undervalued</h2> <p>With AtriCure last closing at US$39.06 against a most followed fair value of US$50, the narrative implies meaningful upside tied to growth and margin lift.</p> <p><em>Positive volume trends from new product launches, combined with operational efficiencies (evidenced by SG&amp;A and R&amp;D growth below revenue growth), are driving operating leverage, which should improve net margins and profitability as the business continues to scale.</em></p> <p>Read the complete narrative.</p> <p>Want to see what kind of revenue ramp and margin shift need to line up to support that higher value? The narrative leans on faster growth, improving profitability, and a future earnings multiple that is far from ordinary. Curious which assumptions really carry this story and how they tie back to that US$50 figure?</p> <p><strong>Result: Fair Value of $50 (UNDERVALUED)</strong></p> <p>Have a read of the narrative in full and understand what's behind the forecasts.</p> <p>However, this depends on key uncertainties, including pressure from pulsed field ablation competitors and the risk that heavy R&amp;D spending does not translate into stronger margins.</p> <p>Find out about the key risks to this AtriCure narrative.</p> <h2>Another View: SWS DCF Flags a Very Different Story</h2> <p>While the popular narrative points to AtriCure being 21.9% undervalued at US$39.06 versus a US$50 fair value, the SWS DCF model is far more cautious. It estimates fair value at just US$0.77, which implies the shares are trading well above that level. Which set of assumptions feels closer to what you believe?</p> <p>Look into how the SWS DCF model arrives at its fair value.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9dadb711-4348-4c35-9471-a52cce87f663/chart/dcf?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9dadb711-4348-4c35-9471-a52cce87f663/chart/dcf"/><figcaption>ATRC Discounted Cash Flow as at Jan 2026</figcaption></figure><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out AtriCure for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 865 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2> Build Your Own AtriCure Narrative</h2> <p>If you look at the numbers and come to a different conclusion, or simply prefer your own research, you can build a custom thesis in just a few minutes with Do it your way.</p> <p>A great starting point for your AtriCure research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.</p> <h2>Looking for more investment ideas?</h2> <p>If you have reached this point, do not stop your research at a single company. Broader idea generation can help you spot opportunities you might otherwise miss.</p> <ul> <li>Spot potential mispricings by scanning these 865 undervalued stocks based on cash flows that may offer a margin of safety based on their cash flow profiles.</li> <li>Ride powerful technology shifts by checking out these 24 AI penny stocks that sit at the intersection of artificial intelligence and rapid revenue expansion.</li> <li>Stay ahead of digital finance trends by reviewing these 19 cryptocurrency and blockchain stocks that are tied to cryptocurrency and blockchain themes before the crowd catches on.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

ATRC

<p>AtriCure (ATRC) has issued a preliminary earnings update indicating a shift towards profitability by 2026, with projected double-digit revenue growth and improved adjusted EBITDA. Despite a recent share price increase, long-term returns remain modest, with a 1.53% return over one year and a 33% decline over five years. The stock is currently viewed as 21.9% undervalued at $39.06, with a fair value estimate of $50. However, a cautious discounted cash flow model suggests a fair value of only $0.77, highlighting differing perspectives on the company's future growth and profitability.</p>

A Look At AtriCure (ATRC) Valuation After Earnings Update Signals Profitability Shift